IOVA Live signals | Maximize Profits with Getagraph.com

BUY 769 min ago

@ $11.50

Issued: 25 Apr 2024 @ 15:41

Return: 0.35%

Previous signal: Apr 25 - 12:02

Previous signal: Sell

Return: 1.32 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):
Our systems believe the stock currently is undervalued by 0.60% compare to its pairs and should correct upwards.

Stats
Today's Volume	3.30M
Average Volume	8.98M
Market Cap	3.22B
EPS	$0 ( 2024-02-28 )
Next earnings date	( $-0.450 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.11
ATR14	$0.484 (4.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Vogt Frederick G	Buy	20 834	Common Stock
2024-04-15	Vogt Frederick G	Sell	8 851	Common Stock
2024-04-15	Vogt Frederick G	Sell	20 834	Restricted Stock Units
2024-04-15	Graf Finckenstein Friedrich	Buy	2 812	Common Stock
2024-04-15	Graf Finckenstein Friedrich	Sell	1 427	Common Stock

INSIDER POWER
94.65
Last 99 transactions
Buy: 13 607 426 \| Sell: 449 378

Correlation (AI algo v.1.1b): Undervalued: 0.60% $11.60 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: -0.26 (neutral)

Short: 0.79 (moderate)

Signal:(54) Neutral

Iovance Biotherapeutics Correlation

10 Most Positive Correlations
VEEE	0.852
PIK	0.851
ASTR	0.845
LITE	0.843
NXTC	0.843
HNNA	0.84
TLIS	0.835
ISUN	0.835
DRIO	0.833
ATER	0.828

10 Most Negative Correlations
AMRB	-0.9
BILI	-0.852
MMAC	-0.848
NETE	-0.839
MDLZ	-0.821
MRCC	-0.811
OFS	-0.811
NRIM	-0.809
OLK	-0.802
SFM	-0.801

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Iovance Biotherapeutics Correlation - Currency/Commodity

0.10
( neutral )

-0.69
( moderate negative )

0.00
( neutral )

0.33
( neutral )

0.28
( neutral )

-0.44
( neutral )

Iovance Biotherapeutics Financials

Annual	2023
Revenue:	$1.19M
Gross Profit:	$-31.94M (-2 686.12 %)
EPS:	$-1.890

FY	2023
Revenue:	$1.19M
Gross Profit:	$-31.94M (-2 686.12 %)
EPS:	$-1.890

FY	2022
Revenue:	$0
Gross Profit:	$-21.14M (0.00 %)
EPS:	$-2.45

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.20

Financial Reports:

No articles found.

Iovance Biotherapeutics

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.